First AD

Second AD

For patients receiving myelosuppressive chemotherapy for breast and lung cancer, same-day pegfilgrastim to combat febrile neutropenia is safe and effective. 

In real-world studies, the trastuzumab biosimilars Kanjinti and Zedora demonstrate comparable safety vs Herceptin for breast and gastrointestinal cancer. 

The Oncology Care Model lowers use of supportive-care medications and boosts filgrastim biosimilar use.

Oncologists’ use of 3 biosimilars soared from 2019 to 2020. 

Texas Oncology’s automatic biosimilar switching program led to single-month savings of $4 million (21%) among 460 health care practitioners. 

Pegfilgrastim administered on the same day as myelosuppressive chemotherapy to ward off febrile neutropenia (FN) 

 increase the incidence of FN, investigators reported.

The trastuzumab biosimilars Kanjinti and Zedora delivered safety outcomes 

 to those for the originator product (Herceptin) in real-world breast and gastrointestinal cancer treatment settings.

 in the Oncology Care Model concluded that this alternative model of payment does contribute to less use of certain products, such as denosumab, in various types of cancer.

 started slowly and then gathered momentum. The savings may have been why: Costs per biosimilar prescription were lower than the reference product prescription cost by 42.0%, 29.9%, and 89.5% for trastuzumab, rituximab, and bevacizumab, respectively.

 patients to bevacizumab, trastuzumab, and rituximab starting in July 2020 and reported hefty savings per administration: $550 for bevacizumab, $850 for trastuzumab, and $1400 for rituximab.

News

Polls

Conference

Oncology

ASCO

Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting. 

Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?